NCT02465944

A Pilot Study of FFP104 in Subjects With Crohn's Disease

A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Fast Forward Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease

Conditions

• Crohn's Disease

Interventions

Type	Name	Description
DRUG	FFP104	Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
DRUG	Placebo	Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-08-01
• Completion: 2017-12-01
• First posted: 2015-06-09
• Last updated: 2016-08-24

Locations

2 sites across 2 countries: Belgium, Netherlands